Latest news
An AI Drug Company Named a Candidate for Dry Macular Degeneration, and the Target Is Undisclosed - Medical DailyMedical Daily · Fri, 07 Aug 2026 11:40:26 GMTInsilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging - Insilico MedicineInsilico Medicine · Thu, 06 Aug 2026 09:47:23 GMTAI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging - eurekalert.orgeurekalert.org · Thu, 06 Aug 2026 03:38:35 GMTInsilico Nominates AI-Designed ISM9077, Potential First-in-Class Y Inhibitor, as Preclinical Candidate - Bioengineer.orgBioengineer.org · Thu, 06 Aug 2026 03:03:47 GMTInsilico Medicine launches AI drug discovery benchmarking platform - Drug Target ReviewDrug Target Review · Fri, 31 Jul 2026 07:00:00 GMTInsilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science - Insilico MedicineInsilico Medicine · Thu, 30 Jul 2026 07:00:00 GMT